Ocumension Stages $184 Million HK IPO; Climbs 152% on First Day
publication date: Jul 10, 2020
Ocumension, a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. Founded in 2017, Ocumension was incubated by 6 Dimensions Capital and now has built a portfolio of 16 ophthalmology drugs for China development, mainly through in-licensings. The portfolio includes three assets at or near clinical stage, and five candidates in preclinical development The company has raised $200 million in venture capital, including a $180 million B round one year ago. More details....
Stock Symbol: (HK 1477)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.